Corrigendum: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

Shimeng Bai,Tianhan Yang,Cuisong Zhu,Meiqi Feng,Li Zhang,Ziling Zhang,Xiang Wang,Rui Yu,Xinghao Pan,Chen Zhao,Jianqing Xu,Xiaoyan Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1146466

IF: 7.3

2023-01-26

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.1099991.].

immunology

What problem does this paper attempt to address?

A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

Shimeng Bai,Tianhan Yang,Cuisong Zhu,Meiqi Feng,Li Zhang,Ziling Zhang,Xiang Wang,Rui Yu,Xinghao Pan,Chen Zhao,Jianqing Xu,Xiaoyan Zhang

DOI: https://doi.org/10.3389/fimmu.2022.1099991

IF: 7.3

2023-01-18

Frontiers in Immunology

Abstract:Background: Rabies is a lethal zoonotic disease that kills approximately 60,000 people each year. Although inactivated rabies vaccines are available, multiple-dose regimensare recommended for pre-exposure prophylaxis or post-exposure prophylaxis,which cuts down the cost- and time-effectiveness, especially in low- and middle incomecountries. Methods: We developed a nucleoside-modified Rabies mRNA-lipid nanoparticle vaccine (RABV-G mRNA-LNP) encoding codon-optimized viral glycoprotein and assessed the immunogenicity and protective efficacy of this vaccine in mice comparing to a commercially available inactivated vaccine. Results: We first showed that, when evaluated in mice, a single vaccination of RABV-G mRNA with a moderate or high dose induces more potent humoral and T-cell immune responses than that elicited by three inoculations of the inactivated vaccine. Importantly, mice receiving a single immunization of RABV-G mRNA, even at low doses, showed full protection against the lethal rabies challenge. We further demonstrated that the humoral immune response induced by single RABV-G mRNA vaccination in mice could last for at least 25 weeks, while a two-dose strategy could extend the duration of the highly protective response to one year or even longer. In contrast, the three-dose regimen of inactivated vaccine failed to do so. Conclusion: Our study confirmed that it is worth developing a single-dose nucleoside-modified Rabies mRNA-LNP vaccine, which could confer much prolonged and more effective protection.

immunology
Erratum: Virus-like particles are efficient tools for boosting mRNA-induced antibodies

DOI: https://doi.org/10.3389/fimmu.2023.1183189

IF: 7.3

2023-03-21

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.864718.].

immunology
Corrigendum: Immunological Characteristics of a Recombinant Alphaherpesvirus with an Envelope-Embedded Cap Protein of Circovirus.

Chenhe Lu,Haimin Li,Wenjing Chen,Hui Li,Jiayu Ma,Peng,Yan,Weiren Dong,Yulan Jin,Shiyue Pan,Shaobin Shang,Jinyan Gu,Jiyong Zhou

DOI: https://doi.org/10.3389/fimmu.2024.1515309

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2024.1438371.].
Publisher Correction: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Jingyun Yang,Wei Wang,Zimin Chen,Shuaiyao Lu,Fanli Yang,Zhenfei Bi,Linlin Bao,Fei Mo,Xue Li,Yong Huang,Weiqi Hong,Yun Yang,Yuan Zhao,Fei Ye,Sheng Lin,Wei Deng,Hua Chen,Hong Lei,Ziqi Zhang,Min Luo,Hong Gao,Yue Zheng,Yanqiu Gong,Xiaohua Jiang,Yanfeng Xu,Qi Lv,Dan Li,Manni Wang,Fengdi Li,Shunyi Wang,Guanpeng Wang,Pin Yu,Yajin Qu,Li Yang,Hongxin Deng,Aiping Tong,Jiong Li,Zhenling Wang,Jinliang Yang,Guobo Shen,Zhiwei Zhao,Yuhua Li,Jingwen Luo,Hongqi Liu,Wenhai Yu,Mengli Yang,Jingwen Xu,Junbin Wang,Haiyan Li,Haixuan Wang,Dexuan Kuang,Panpan Lin,Zhengtao Hu,Wei Guo,Wei Cheng,Yanlin He,Xiangrong Song,Chong Chen,Zhihong Xue,Shaohua Yao,Lu Chen,Xuelei Ma,Siyuan Chen,Maling Gou,Weijin Huang,Youchun Wang,Changfa Fan,Zhixin Tian,Ming Shi,Fu-Sheng Wang,Lunzhi Dai,Min Wu,Gen Li,Guangyu Wang,Yong Peng,Zhiyong Qian,Canhua Huang,Johnson Yiu-Nam Lau,Zhenglin Yang,Yuquan Wei,Xiaobo Cen,Xiaozhong Peng,Chuan Qin,Kang Zhang,Guangwen Lu,Xiawei Wei

DOI: https://doi.org/10.1038/s41586-020-03108-4

IF: 64.8

2021-01-19

Nature

Abstract:A Correction to this paper has been published: https://doi.org/10.1007/s00125-020-03108-4.

multidisciplinary sciences
Corrigendum: Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

Ruodan Xu,Mingfei Shi,Jing Li,Ping Song,Ning Li

DOI: https://doi.org/10.3389/fbioe.2020.01026

IF: 5.7

2020-09-09

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2020.00862.].

multidisciplinary sciences
Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Pingping Ren,Luying Lu,Shasha Cai,Jianghua Chen,Weiqiang Lin,Fei Han

DOI: https://doi.org/10.3389/fimmu.2024.1513491

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.713540.].
Corrigendum: Advancement in the Development of Therapeutics Against Zika Virus Infection

Kangchen Li,Qianting Ji,Shibo Jiang,Naru Zhang

DOI: https://doi.org/10.3389/fcimb.2022.1006226

IF: 6.073

2022-01-01

Frontiers in Cellular and Infection Microbiology

Abstract:[This corrects the article DOI: 10.3389/fcimb.2022.946957.].
Corrigendum: Designing a polyvalent vaccine targeting multiple strains of varicella zoster virus using integrated bioinformatics approaches

Nurul Amin Rani,Abu Tayab Moin,Rajesh Patil,Tanjin Barketullah Robin,Talha Zubair,Nafisa Nawal,Md Razwan Sardar Sami,Md Masud Morshed,Jingbo Zhai,Mengzhou Xue,Mohabbat Hossain,Chunfu Zheng,Mohammed Abul Manchur,Nazneen Naher Islam

DOI: https://doi.org/10.3389/fmicb.2024.1498557

2024-10-08

Abstract:[This corrects the article DOI: 10.3389/fmicb.2023.1291868.].
Corrigendum: Screening and identification of nucleocapsid protein-nanobodies that inhibited Newcastle disease virus replication in DF-1 cells

Wenqi Fan,Pinpin Ji,Xuwen Sun,Min Kong,Ning Zhou,Qiang Zhang,Ying Wang,Qianqian Liu,Xiaoxuan Li,En-Min Zhou,Qin Zhao,Yani Sun

DOI: https://doi.org/10.3389/fmicb.2022.1045834

IF: 5.2

2022-10-31

Frontiers in Microbiology

Abstract:[This corrects the article DOI: 10.3389/fmicb.2022.956561.].

microbiology
Corrigendum: Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants

Franciane Mouradian Emidio Teixeira,Luana de Mendonça Oliveira,Anna Cláudia Calvielli Castelo Branco,Ricardo Wesley Alberca,Emanuella Sarmento Alho de Sousa,Bruno Henrique de Sousa Leite,Wenny Camilla dos Santos Adan,Alberto José da Silva Duarte,Roberto Dias Lins,Maria Notomi Sato,Isabelle Freire Tabosa Viana,Ricardo Wesley Alberca,Maria Notomi Sato

DOI: https://doi.org/10.3389/fimmu.2024.1376059

IF: 7.3

2024-02-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2024.1307546.].

immunology
Corrigendum: COVIEdb: A Database for Potential Immune Epitopes of Coronaviruses.

Jingcheng Wu,Wenfan Chen,Jingjing Zhou,Wenyi Zhao,Yisheng Sun,Hanping Zhu,Pingping Yao,Shuqing Chen,Jianmin Jiang,Zhan Zhou

DOI: https://doi.org/10.3389/fphar.2020.646111

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2020.572249.].
Corrigendum: Low Frequency Ultrasound with Injection of NMO-IgG and Complement Produces Lesions Different from Experimental Autoimmune Encephalomyelitis Mice

Weiwei Xiang,Chong Xie,Jiaying Luo,Wei Zhang,Xinxin Zhao,Hong Yang,Yu Cai,Jie Ding,Yishu Wang,Yong Hao,Ying Zhang,Yangtai Guan

DOI: https://doi.org/10.3389/fimmu.2022.842300

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2021.727750.].
Corrigendum: Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

Shi Zou,Wei Guo,Songjie Wu,Fangzhao Ming,Yuting Tan,Mengmeng Wu,Weiming Tang,Ke Liang

DOI: https://doi.org/10.3389/fimmu.2024.1494940

2024-09-25

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.988304.].
Corrigendum: Mind the “vaccine fatigue”

Zhaohui Su,Ali Cheshmehzangi,Dean McDonnell,Claudimar Pereira da Veiga,Yu-Tao Xiang

DOI: https://doi.org/10.3389/fimmu.2022.1122354

IF: 7.3

2023-01-04

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.839433.].

immunology
A single immunization with core–shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs

Jiawu Wan,Jianmei Yang,Zongmei Wang,Ruizhong Shen,Chengguang Zhang,Yuntao Wu,Ming Zhou,Huanchun Chen,Zhen F. Fu,Haiwei Sun,Yinglei Yi,Haifa Shen,Hangwen Li,Ling Zhao

DOI: https://doi.org/10.1080/22221751.2023.2270081

2023-11-22

Emerging Microbes & Infections

Abstract:The persistence and clinical consequences of rabies virus (RABV) infection have prompted global efforts to develop a safe and effective vaccines against rabies. mRNA vaccines represent a promising option against emerging and re-emerging infectious diseases, gaining particular interest since the outbreak of COVID-19. Herein, we report the development of a highly efficacious rabies mRNA vaccine composed of sequence-modified mRNA encoding RABV glycoprotein (RABV-G) packaged in core-shell structured lipopolyplex (LPP) nanoparticles, named LPP-mRNA-G. The bilayer structure of LPP improves protection and delivery of RABV-G mRNA and allows gradual release of mRNA molecules as the polymer degrades. The unique core-shell structured nanoparticle of LPP-mRNA-G facilitates vaccine uptake and demonstrates a desirable biodistribution pattern with low liver targeting upon intramuscular immunization. Single administration of low-dose LPP-mRNA-G in mice elicited potent humoral immune response and provided complete protection against intracerebral challenge with lethal RABV. Similarly, single immunization of low-dose LPP-mRNA-G induced high levels of virus-neutralizing antibody titers in dogs. Collectively, our data demonstrate the potential of LPP-mRNA-G as a promising next-generation rabies vaccine used in human and companion animals.

immunology,infectious diseases,microbiology
Corrigendum: Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Kun Li,Sheng Wang,Yimei Cao,Huang Bao,Pinghua Li,Pu Sun,Xingwen Bai,Yuanfang Fu,Xueqing Ma,Jing Zhang,Dong Liu,Yingli Chen,Xuerong Liu,Fanglan An,Faju Wu,Zengjun Lu,Zaixin Liu

DOI: https://doi.org/10.3389/fimmu.2020.00286

IF: 7.3

2020-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.02870.].
Corrigendum: DEAD-Box Helicase DDX6 Facilitated RIG-I-Mediated Type-I Interferon Response to EV71 Infection.

Rui Zhang,Min Cheng,Bingxin Liu,Meng Yuan,Deyan Chen,Yujiong Wang,Zhiwei Wu

DOI: https://doi.org/10.3389/fcimb.2021.789723

IF: 6.073

2021-01-01

Frontiers in Cellular and Infection Microbiology

Abstract:[This corrects the article DOI: 10.3389/fcimb.2021.725392.].
Corrigendum: Orally administered recombinant Lactobacillus expressing African swine fever virus antigens that induced immunity responses

Hongliang Zhang,Saisai Zhao,Haojie Zhang,Yu Shen,Peijun Zhang,Hu Shan,Xiulei Cai

DOI: https://doi.org/10.3389/fmicb.2024.1529166

IF: 5.2

2024-12-03

Frontiers in Microbiology

Abstract:This article is a correction to: Orally administered recombinant Lactobacillus expressing African swine fever virus antigens that induced immunity responses

microbiology
Correction: Wang Et Al. A VLP-Based Vaccine Displaying HBHA and MTP Antigens of Mycobacterium Tuberculosis Induces Potentially Protective Immune Responses in M. Tuberculosis H37Ra Infected Mice. Vaccines 2023, 11, 941.

Juan Wang,Tao Xie,Inayat Ullah,Youjun Mi,Xiaoping Li,Yang Gong,Pu He,Yuqi Liu,Fei Li,Jixi Li,Zengjun Lu,Bingdong Zhu

DOI: https://doi.org/10.3390/vaccines11091454

2023-01-01

Vaccines

Abstract:Concerns were brought to the attention of the journal's editorial office after the paper was published [...].
An mRNA vaccine against rabies provides strong and durable protection in mice

Miao Li,Enyue Fang,Yunpeng Wang,Leitai Shi,Jia Li,Qinhua Peng,Xingxing Li,Danhua Zhao,Xiaohui Liu,Xinyu Liu,Jingjing Liu,Hongshan Xu,Hongyu Wang,Yanqiu Huang,Ren Yang,Guangzhi Yue,Yue Suo,Xiaohong Wu,Shouchun Cao,Yuhua Li

DOI: https://doi.org/10.3389/fimmu.2023.1288879

IF: 7.3

2023-10-26

Frontiers in Immunology

Abstract:Introduction Rabies is a serious public health problem worldwide for which an effective treatment method is lacking but can be prevented by vaccines. Current vaccines are produced in cell or egg cultures, which are both costly and time consuming. Methods Here, a non-replicating mRNA vaccine (RV021) encoding the rabies virus glycoprotein was developed in vitro , and its immunogenicity and protective efficacy against live virus was evaluated in mice. Results A two-dose vaccination with 1 μg of RV021 at 7-day intervals induced a protective level of neutralizing antibody that was maintained for at least 260 days. RV021 induced a robust cellular immune response that was significantly superior to that of an inactivated vaccine. Two doses of 1 μg RV021 provided full protection against challenge with CVS of 30~60-fold lethal dose, 50%. Vaccine potency testing (according to the National Institutes of Health) in vivo revealed that the potency of RV021 at 15 μg/dose was 7.5 IU/dose, which is substantially higher than the standard for lot release of rabies vaccines for current human use. Conclusion The mRNA vaccine RV021 induces a strong protective immune response in mice, providing a new and promising strategy for human rabies prevention and control.

immunology

Corrigendum: A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

Erratum: Virus-like particles are efficient tools for boosting mRNA-induced antibodies

Corrigendum: Immunological Characteristics of a Recombinant Alphaherpesvirus with an Envelope-Embedded Cap Protein of Circovirus.

Publisher Correction: A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Corrigendum: Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System

Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Corrigendum: Advancement in the Development of Therapeutics Against Zika Virus Infection

Corrigendum: Designing a polyvalent vaccine targeting multiple strains of varicella zoster virus using integrated bioinformatics approaches

Corrigendum: Screening and identification of nucleocapsid protein-nanobodies that inhibited Newcastle disease virus replication in DF-1 cells

Corrigendum: Enhanced immunogenicity and protective efficacy in mice following a Zika DNA vaccine designed by modulation of membrane-anchoring regions and its association to adjuvants

Corrigendum: COVIEdb: A Database for Potential Immune Epitopes of Coronaviruses.

Corrigendum: Low Frequency Ultrasound with Injection of NMO-IgG and Complement Produces Lesions Different from Experimental Autoimmune Encephalomyelitis Mice

Corrigendum: Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV

Corrigendum: Mind the “vaccine fatigue”

A single immunization with core–shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs

Corrigendum: Development of Foot-and-Mouth Disease Virus-Neutralizing Monoclonal Antibodies Derived From Plasmablasts of Infected Cattle and Their Germline Gene Usage

Corrigendum: DEAD-Box Helicase DDX6 Facilitated RIG-I-Mediated Type-I Interferon Response to EV71 Infection.

Corrigendum: Orally administered recombinant Lactobacillus expressing African swine fever virus antigens that induced immunity responses

Correction: Wang Et Al. A VLP-Based Vaccine Displaying HBHA and MTP Antigens of Mycobacterium Tuberculosis Induces Potentially Protective Immune Responses in M. Tuberculosis H37Ra Infected Mice. Vaccines 2023, 11, 941.

An mRNA vaccine against rabies provides strong and durable protection in mice